<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1010">
  <stage>Registered</stage>
  <submitdate>2/12/2005</submitdate>
  <approvaldate>2/12/2005</approvaldate>
  <nctid>NCT00263588</nctid>
  <trial_identification>
    <studytitle>Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer</studytitle>
    <scientifictitle>A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EGF105084</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Neoplasms, Breast</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - lapatinib

Experimental: single arm - 750 mg laptinib administered orally twice daily


Treatment: drugs: lapatinib
tyrosine kinase inhibitor

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Response to lapatinib in patients with progressive brain metastases from ErbB2-overexpressing breast cancer.</outcome>
      <timepoint>baseline to time of best response to treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Improvement in neurological signs and symptoms (NSS), measured using the Neurological Examination Worksheet</outcome>
      <timepoint>baseline to end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients who obtain a CNS objective response or improvement in baseline NSS</outcome>
      <timepoint>baseline to end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of CNS objective response</outcome>
      <timepoint>baseline to end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with CNS disease control (complete response, partial response or stable disease) at 6 months of lapatinib therapy</outcome>
      <timepoint>baseline to end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to progression at any site</outcome>
      <timepoint>baseline to time of disease progression</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>baseline to time of death or lost ot follow up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Site of first progression and cause of death</outcome>
      <timepoint>baseline to time of death or lost ot follow up</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Qualitative and quantitative toxicities associated with oral lapatinib, given at a dose of 750 mg twice a day</outcome>
      <timepoint>baseline to end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relationship of PET uptake at Baseline and Week 1, as predictors of response (for those patients whose site obtained PET qualifications).</outcome>
      <timepoint>baseline to end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relationship between genetic variants in select candidate genes in the host and the efficacy and safety of lapatinib</outcome>
      <timepoint>baseline to end of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion criteria:

          -  Signed Informed Consent

          -  ErbB2(HER2)overexpressing breast cancer.

          -  Brain lesion(s) which are progressing.

          -  Prior treatment of brain metastases with Whole Brain Radiotherapy (WBR)and/or
             Stereotactic Radiosurgery (SRS).

          -  Prior treatment with trastuzumab (Herceptin), either alone or in combination with
             chemotherapy.

          -  Cardiac ejection fraction(LVEF)within the institutional range of normal as measured by
             Echocardiogram.

          -  Able to swallow an oral medication.

          -  Adequate kidney and liver function.

          -  Adequate bone marrow function.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Exclusion criteria:

          -  Pregnant or lactating females.

          -  Conditions that would effect the absorption of an oral drug.

          -  History of immediate or delayed hypersensitivity reaction to gadolinium contrast
             agents.

          -  Pre-existing severe cerebral vascular disease, such as stroke involving a major
             vessel.

          -  Serious medical or psychiatric disorder that would interfere with the patient's safety
             or informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>2/12/2005</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>244</actualsamplesize>
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/12/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,VIC,WA</recruitmentstate>
    <hospital>Novartis Investigative Site - North Sydney</hospital>
    <hospital>Novartis Investigative Site - Herston</hospital>
    <hospital>Novartis Investigative Site - South Brisbane</hospital>
    <hospital>Novartis Investigative Site - Box Hill</hospital>
    <hospital>Novartis Investigative Site - Ringwood East</hospital>
    <hospital>Novartis Investigative Site - Perth</hospital>
    <hospital>Novartis Investigative Site - Adelaide</hospital>
    <postcode>2060 - North Sydney</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>4101 - South Brisbane</postcode>
    <postcode>3128 - Box Hill</postcode>
    <postcode>3135 - Ringwood East</postcode>
    <postcode>6000 - Perth</postcode>
    <postcode>5000 - Adelaide</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Mexico</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Salzburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Bruxelles</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>British Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Dijon Cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 05</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Toulouse cedex</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Bayern</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Hessen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Neo Faliro</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Bangalore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Mumbai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Emilia-Romagna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Lombardia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Umbria</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Saitama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Olsztyn</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warszawa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Uppsala</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Geneve</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Locarno</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Tainan County</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Lancashire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Brighton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Determine how safe and effective lapatinib is when used to treat patients with ErbB2
      overexpressing breast cancer that has spread to the brain and is still progressing there even
      after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic
      radiosurgery) to the brain. Lapatinib is an oral drug that will be taken every day. Tests for
      safety and efficacy will be performed every 4 weeks or 8 weeks (depending on the test) during
      the course of the study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00263588</trialwebsite>
    <publication>Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, Roché H, Liu MC, Greil R, Ciruelos E, Loibl S, Gori S, Wardley A, Yardley D, Brufsky A, Blum JL, Rubin SD, Dharan B, Steplewski K, Zembryki D, Oliva C, Roychowdhury D, Paoletti P, Winer EP. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009 Feb 15;15(4):1452-9. doi: 10.1158/1078-0432.CCR-08-1080.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>